HomeONCY • NASDAQ
add
Oncolytics Biotech Inc
Previous close
$0.59
Day range
$0.55 - $0.60
Year range
$0.47 - $1.53
Market cap
45.89M USD
Avg Volume
309.12K
P/E ratio
-
Dividend yield
-
Financials
Income Statement
Revenue
Net income
| (CAD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 8.44M | -4.66% |
Net income | -8.02M | -103.01% |
Net profit margin | — | — |
Earnings per share | -0.10 | 9.91% |
EBITDA | -8.43M | 4.56% |
Effective tax rate | -0.29% | — |
Balance Sheet
Total assets
Total liabilities
| (CAD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 15.94M | -54.34% |
Total assets | 20.19M | -48.00% |
Total liabilities | 14.20M | 26.18% |
Total equity | 5.98M | — |
Shares outstanding | 86.42M | — |
Price to book | 8.48 | — |
Return on assets | -94.91% | — |
Return on capital | -245.72% | — |
Cash Flow
Net change in cash
| (CAD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -8.02M | -103.01% |
Cash from operations | -7.85M | -28.12% |
Cash from investing | -6.00K | -100.00% |
Cash from financing | 3.34M | 91.68% |
Net change in cash | -3.66M | 27.88% |
Free cash flow | -4.62M | 44.28% |
About
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Founded
1998
Headquarters
Website
Employees
28
